Inhibition of the Interaction Between Viral Spike Proteins of SARS-CoV-2 and Human Angiotensin-Converting Enzyme 2 (hACE2)

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes specific peptides (short chains of amino acids) designed to block the interaction between the SARS-CoV-2 viral spike protein and the human ACE2 receptor. By preventing this critical interaction, the peptides aim to stop the virus from entering human cells, offering a possible treatment for COVID-19.

Use CasesContent extracted from patent full text and abstract with AI.

• Therapeutic drug for treating COVID-19 patients
• Preventative treatment to reduce the risk of SARS-CoV-2 infection
• Research tool for studying virus-host interactions
• Potential base for developing new antiviral agents

BenefitsContent extracted from patent full text and abstract with AI.

• May directly inhibit SARS-CoV-2 infection by blocking viral entry into cells
• Could reduce severity and spread of COVID-19
• Provides a targeted approach with potentially fewer side effects compared to broad-spectrum antivirals
• Supports rapid development and adaptation to emerging viral variants

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

Described is a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and/or SEQ ID NO: 5, as well as homologues, fragments and parts thereof, its use for inhibiting the interaction of the viral spike protein of SARS-CoV-2 with the human angiotensin-converting enzyme hACE2, and such a peptide for use as a medicament, in particular for use in the treatment of COVID-19.